Alethia Young
Analyst at Cantor Fitzgerald
Ticker Coverage
Sector Coverage
Sample Research
Gilead Sciences Inc. (GILD - $68.16)
Mentions in the News
FDA Green-Lighting Drugs at Breakneck Speed -- and Raising Alarm...
The U.S. is approving new drugs so fast that companies are now preparing for a green light months in advance of the scheduled decision date, a pace that’s helping patients with rare or untreatable diseases but raising alarm among consumer advocates.
Published: Dec 6 2019
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. Cantor Fitzgerald analyst Alethia Young maintained a Neutral rating and $300 price …
Published: Dec 6 2019
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the …
Published: Dec 5 2019
Show More..
Earnings Call Transcripts
Arrowhead Research Corp (ARWR) Q4 2019 Earnings Call Transcript
ARWR earnings call for the period ending September 30, 2019.
Published: Nov 26 2019
Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT
Q4 2019 Arrowhead Pharmaceuticals Inc Earnings Call
Published: Nov 26 2019
Show More..
Would you like to be included in the directory? Let us know!
© Street Contxt. All Rights Reserved.